《大行》大華繼顯升中國平安(02318.HK)目標價至69元 評級「買入」
大華繼顯發表研究報告指,中國平安(02318.HK)上半年稅後營運利潤按年升3.7%,大致上符合預期,主要得益於財產險及意外險業務綜合成本率表現強勁,以及資產管理業務在去風險化後的復甦,這部分抵消了平安銀行盈利表現疲軟。
該行表示,受惠今年第二季首年保費增長復甦以及利潤率持續增長,新業務價值按年加速增長至40%。管理層對營業利潤和新業務價值增長動能在下半年持續保持樂觀。
該行將公司在2025年至2027年各年稅後營運利潤上調5.7%、1.3%及1.2%,而各年新價值業務預測上調8.1%、7.7%及5.7%,目標價由61元上調至69元,維持其「買入」評級。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.